GlassScriptPhysician profile
Jason J Menges
NPI 1982691242
$14,764.07
in general payments reported to CMS, 2019-2025
53 companies · $3,372 in 2025
The $3,372 reported for 2025 was more than what 96% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,777 · 2022: $3,043 · 2023: $2,621 · 2024: $2,950 · 2025: $3,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,645 · Consulting Fee: $175 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,645.13 |
| Consulting Fee | $175.00 |
| Education | $124.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,490.39 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,480.94 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,009.68 | 2021-2025 | Prolia, Evenity, Tepezza |
| Abbott Laboratories | $970.34 | 2021-2025 | Freestyle Libre 3, Afinion 2, Freestyle Libre 2 |
| Dexcom, INC. | $785.04 | 2021-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $653.42 | 2021-2025 | |
| Recordati_rare_diseases_inc. | $620.80 | 2021-2025 | Isturisa, Signifor Lar |
| Xeris Pharmaceuticals, INC. | $592.09 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Astrazeneca Pharmaceuticals LP | $589.92 | 2021-2025 | Farxiga |
| Corcept Therapeutics | $526.47 | 2021-2025 | Korlym |
| Insulet Corporation | $498.99 | 2021-2025 | Omnipod |
| Astellas Pharma US INC | $353.14 | 2023-2025 | Veozah |
| Radius Health, INC. | $340.85 | 2021-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $329.23 | 2021-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $305.68 | 2021-2025 |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $298.03 | 2021-2024 | |
| Antares Pharma, INC. | $292.91 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Abbvie INC. | $290.60 | 2021-2025 | |
| Tandem Diabetes Care, INC. | $289.33 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $264.84 | 2021-2025 | Intellis Adaptivestim, Minimed 780g |
| Novartis Pharmaceuticals Corporation | $231.28 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $228.39 | 2021-2025 | Unithroid |
| Amarin Pharma, INC. | $227.63 | 2021-2022 | |
| Pfizer INC. | $171.84 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $154.50 | 2021-2023 | Segluromet, Steglatro, Steglujan |
| Cequr Corporation | $127.09 | 2024-2025 | Cequr Simplicity |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2022 | |
| Chiesi USA, INC. | $116.44 | 2024-2025 | Mycapssa, Myalept |
| Ascendis Pharma Endocrinology INC | $114.40 | 2025 | Yorvipath |
| Amryt Pharma Holdings LTD | $111.25 | 2021-2023 | Myalept, Mycapssa |
| Ibsa Pharma INC. | $105.77 | 2022-2024 | Tirosint, Licart, Licart |
| Aimmune Therapeutics, INC. | $99.03 | 2024-2025 | Zenpep |
| Eusa Pharma (US) LLC | $92.71 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $80.65 | 2023-2025 | Evkeeza |
| Ipsen Biopharmaceuticals, INC | $80.01 | 2021-2022 | |
| Nevro Corp. | $79.57 | 2022-2024 | Senza |
| Sequel Med Tech, LLC | $73.94 | 2025 | Twiist |
| Currax Pharmaceuticals LLC | $67.22 | 2021-2024 | Nexletol, Contrave, Nexlizet |
| Beta Bionics, INC. | $61.34 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Alexion Pharmaceuticals, INC. | $50.17 | 2024-2025 | Strensiq |
| Esperion Therapeutics, INC. | $48.44 | 2021-2024 | Nexletol |
| Ultragenyx Pharmaceutical INC. | $39.95 | 2021 | |
| Globus Medical, INC. | $39.11 | 2025 | Senza |
| Neurocrine Biosciences, INC. | $35.96 | 2024-2025 | |
| Almatica Pharma LLC | $34.73 | 2024-2025 | Teriparatide |
| Kyowa Kirin, INC. | $34.37 | 2024-2025 | Crysvita |
| Horizon Therapeutics Plc | $33.69 | 2023 | Tepezza |
| Echosens North America, INC. | $24.06 | 2025 | Fibroscan |
| Averitas Pharma INC. | $22.94 | 2023 | Qutenza |
| Zealand Pharma US, INC. | $22.61 | 2021 | |
| Halozyme INC | $21.04 | 2023 | |
| Verity Pharmaceuticals INC. | $14.59 | 2025 | Tlando |
| Kowa Pharmaceuticals America, INC. | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Menges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.